The prognosis of breast cancer could be predicted by recently identified protein according to the latest study published in the journal of Molecular and Cellular Biology.
A link between levels of some 1,200 genes that work under the control of an enzyme named as EZH2 and aggressive forms of breast cancer has been highlighted by researchers by using bioinformatic techniques.
“The analysis pipeline that we developed will be useful for stratification of breast cancer patients,” says Elizaveta V. Benevolenskaya of the University of Illinois at Chicago, a researcher on the study. “That stratification will enable clinicians to accurately predict breast cancer progression. The level of expression of a subgroup of EZH2-bound genes could have further predictive value, indicating, for example, that a specific treatment regime is needed.”
The researchers inhibited the expression of EZH2 that causes the re-activation of genes control by using a process of RNA inhibition. The aggressive phenotypes of breast cancer were reduced as a result of this RNA inhibition.
It would be possible to develop such drugs that will target EZH2 and could reduce the risk of aggressive forms of breast cancer. Such drug molecules should be smaller as they could provide several benefits such as;
- Manufacturing and development of smaller molecules is easier and cheaper.
- Such molecules can be easily taken by mouth (orally).
“Besides breast cancer, EZH2 overexpression appears to be associated with a worse prognosis in prostate, endometrial, and melanoma tumors. The computational analysis used in their research could also be helpful for predicting the aggressiveness of these and other cancers, says Benevolenskaya.”
Reference: Alba Jene-Sanz, Váraljai Renáta, Alexandra V. Vilkova, Galina F. Khramtsova3, Andrey. Khramtsov4, Olufunmilayo. Olopade3, Nuria Lopez-Bigas and Elizaveta V.Benevolenskaya. Expression of Polycomb targets 1 predicts breast cancer prognosis. 2013. Mol. Cell. Biol. doi:10.1128/MCB.00426-13
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.